At the European Hematology Association Congress, Innate Pharma and Sanofi presented promising results from their Phase 1/2 study of SAR’579, a Natural Killer Cell Engager (NKCE). SAR’579, targeting CD123, showed significant clinical efficacy in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
The study assessed SAR’579 as monotherapy for blood cancers, including AML, B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). Fifty-nine patients received treatment across various dose levels.
A maximum response rate was observed at a target dose of 1 mg/kg weekly, with five AML patients achieving complete remission (CR). The median treatment duration was 7.9 weeks, and durable CRs (>10 months) were observed in three patients. SAR’579 demonstrated good tolerability up to doses of 6 mg/kg weekly.
These findings support the further development of SAR’579 in the Phase 2 portion of the trial. Ongoing studies aim to explore its potential in patients with leukemia.
Innate Pharma’s ANKET platform enables the development of multi-specific NK cell engagers for cancer treatment. Sanofi leads the SAR’579 development program and is responsible for its advancement through clinical trials.
The Innate-Sanofi collaboration focuses on utilizing Innate’s proprietary technology to create new antibody formats that engage NK cells and enhance antitumor activity. The positive results from the SAR’579 study highlight the potential of this platform in addressing unmet medical needs in blood cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
